Appropriate Interpretation of Urine Drug Screen Results-Recording Presentation

Video Transcription

Video Summary

Good afternoon. Today's webinar covered the appropriate interpretation of urine drug screen results. The webinar was organized and hosted by the American Pharmacists Association and APHA's Pain, Palliative Care, and Addiction SIG. The speakers for the event were Dr. Emily Lapine, a clinical assistant professor at Binghamton University School of Pharmacy and Pharmaceutical Sciences, and Dr. Mark Garofali, a faculty member of the West Virginia University School of Pharmacy and School of Medicine Pain Fellowship Program. Dr. Lapine specializes in the treatment of chronic pain, substance use disorder, and psychiatric illness, while Dr. Garofali is a medicine pain and addiction pharmacist. The webinar discussed the difference between urine drug screenings and urine drug testing. Urine drug screenings are point-of-care tests that provide presumptive results, while urine drug testing is more definitive and holds up in clinical and legal settings. False positives and false negatives can occur with urine drug screenings due to a variety of factors, including cross-reactivity and issues with sample collection and handling. The speakers also discussed the importance of understanding the metabolic pathways of different drugs to avoid misunderstandings when interpreting urine drug test results. Additionally, they addressed the need for regular urine drug monitoring for patients on controlled substances and outlined strategies for discussing unexpected results with patients. The webinar emphasized the importance of continuing patient care and not abandoning patients based solely on urine drug screen or test results. The session concluded with a Q&A session where the speakers addressed questions from the audience. To access additional resources and educational offerings related to urine drug screen interpretation, attendees were directed to visit the PCSS website and social media accounts.

Keywords

webinar

urine drug screen

interpretation

American Pharmacists Association

Dr. Emily Lapine

Dr. Mark Garofali

point-of-care tests

false positives

false negatives

urine drug monitoring